Skip to main content
. 2017 Jun 5;4(4):e360. doi: 10.1212/NXI.0000000000000360

Figure 4. Depletion of lymphocyte subsets following alemtuzumab and cladribine treatment.

Figure 4

Cladribine (CLAD) was administered as weekly courses of CLAD at 0, 5 and 48 and 52 weeks (time of initiation of cycle; inverse triangle) or weekly courses of alemtuzumab (ALEM) at 0 and 52 weeks. The results represent the mean absolute number of peripheral blood lymphocytes (per cubic millimeter) during the CLAD Tablets Treating Multiple Sclerosis Orally (CLARITY) trial in people with relapsing MS (pwRMS) treated with either placebo (circle; n = 68–80), CLAD 3.5 mg/kg (diamond; n = 77–86), CLAD 5.25 mg/kg (hexagon; n = 79–84), and pwRMS in the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, study one (CARE-MS I) trial treated with 12 mg/d ALEM (square; n = 171–184).